voxilaprevir

From Aaushi

Jump to navigation Jump to search

^[1]

Indications

used in combination with sofosbuvir & velpatasvir for treatment of hepatitis C genotypes 1-6 without cirrhosis

More general terms

antiviral agent

Component of

sofosbuvir/velpatasvir/voxilaprevir (Vosevi)

References

↑ FDA News Release. July 18, 2017 FDA approves Vosevi for Hepatitis C https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm567467.htm

Database

PubChem: http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=89921642

Retrieved from "https://aaushi.info/w/index.php?title=A54337&oldid=956731"

↑ Back to top